Saunders Ruth, Siddiqui Salman, Kaur Davinder, Doe Camille, Sutcliffe Amanda, Hollins Fay, Bradding Peter, Wardlaw Andrew, Brightling Christopher E
Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester.
J Allergy Clin Immunol. 2009 Feb;123(2):376-384. doi: 10.1016/j.jaci.2008.10.048. Epub 2008 Dec 10.
Airway smooth muscle (ASM) hyperplasia is a hallmark of asthma that is associated with disease severity and persistent airflow obstruction.
We sought to investigate whether fibrocytes, a population of peripheral blood mesenchymal progenitors, are recruited to the ASM compartment in asthma.
We assessed the number of fibrocytes in bronchial biopsy specimens and peripheral blood from subjects with mild-to-severe refractory asthma versus healthy control subjects. In vitro we investigated potential mechanisms controlling fibrocyte migration toward the ASM bundle.
Fifty-one subjects with asthma and 33 control subjects were studied. In bronchial biopsy specimens, the number of fibrocytes was increased in the lamina propria of subjects with severe refractory asthma (median [interquartile range] number, 1.9/mm(2) [1.7/mm(2)]) versus healthy control subjects (median [interquartile range] number, 0/mm(2) [0.3/mm(2)], P < .0001) and in the ASM bundle of subjects with asthma of all severities (subjects with severe asthma, median [interquartile range] number, 3.8/mm(2) [9.4/mm(2)]; subjects with mild-to-moderate asthma, median [interquartile range] number, 1.1/mm(2) [2.4/mm(2)]); healthy control subjects, (median [interquartile range] number, 0/mm(2) [0/mm(2)]); P = .0004). In the peripheral blood the fibrocyte number was also increased in subjects with severe refractory asthma (median [interquartile range] number, 1.4 x 10(4)/mL [2.6 x 10(4)/mL]) versus healthy control subjects (median [interquartile range] number, 0.4 x 10(4)/mL [1.0 x 10(4)/mL], P = .002). We identified that in vitro ASM promotes fibrocyte chemotaxis and chemokinesis (distance of migration after 4.5 hours, 31 microm [2.9 microm] vs 17 microm [2.4 microm], P = .0001), which was in part mediated by platelet-derived growth factor (mean inhibition by neutralizing antibody, 16% [95% CI, 2% to 32%], P = .03) but not by activation of chemokine receptors.
This study provides the first evidence that fibrocytes are present in the ASM compartment in asthma and that ASM can augment fibrocyte migration. The importance of fibrocytes in the development of ASM hyperplasia and airway dysfunction in asthma remains to be determined.
气道平滑肌(ASM)增生是哮喘的一个标志,与疾病严重程度和持续性气流受限相关。
我们试图研究外周血间充质祖细胞群——纤维细胞是否在哮喘中被募集到ASM区室。
我们评估了轻至重度难治性哮喘患者与健康对照者支气管活检标本和外周血中的纤维细胞数量。在体外,我们研究了控制纤维细胞向ASM束迁移的潜在机制。
研究了51例哮喘患者和33例对照者。在支气管活检标本中,重度难治性哮喘患者固有层中的纤维细胞数量增加(中位数[四分位间距]数量,1.9/mm²[1.7/mm²]),而健康对照者为(中位数[四分位间距]数量,0/mm²[0.3/mm²],P <.0001),并且在所有严重程度的哮喘患者的ASM束中也增加(重度哮喘患者,中位数[四分位间距]数量,3.8/mm²[9.4/mm²];轻至中度哮喘患者中位数[四分位间距]数量,1.1/mm²[2.4/mm²]);健康对照者为(中位数[四分位间距]数量,0/mm²[0/mm²]);P =.0004)。在外周血中,重度难治性哮喘患者的纤维细胞数量也增加(中位数[四分位间距]数量,1.4×10⁴/mL[2.6×10⁴/mL]),而健康对照者为(中位数[四分位间距]数量,0.4×10⁴/mL[1.0×10⁴/mL],P =.002)。我们发现体外ASM可促进纤维细胞趋化性和趋动性(4.5小时后的迁移距离,31微米[2.9微米]对17微米[2.4微米],P =.0001),这部分由血小板衍生生长因子介导(中和抗体的平均抑制率,为16%[95%CI,2%至32%],P =.03)但不是由趋化因子受体激活介导。
本研究提供了首个证据,证明纤维细胞存在于哮喘患者的ASM区室中,并且ASM可增强纤维细胞迁移。纤维细胞在哮喘中ASM增生和气道功能障碍发展中的重要性仍有待确定。